Creator of the article:
Revealed Mar 08, 2025 • 4 minute learn
Article content material
LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) — ACTG, a worldwide scientific trials community centered on HIV and different infectious ailments, at this time introduced knowledge demonstrating that switching to an integrase inhibitor-based antiretroviral routine elevated the chance of weight achieve and cardiometabolic issues over the following 5 years in comparison with remaining on a routine with out an integrase inhibitor. They didn’t discover an elevated danger of main adversarial cardiovascular occasions (MACE), reminiscent of coronary heart assaults or strokes. These outcomes from the REPRIEVE (The Randomized Trial to Forestall Vascular Occasions in HIV) examine have been shared because the late breaking poster presentation, “Threat of Weight problems, Cardiometabolic Illness and MACE after Change to an Integrase Inhibitor in REPRIEVE” on the 2025 Convention on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California.
Commercial 2
Article content material
Article content material
Article content material
REPRIEVE was the primary large-scale scientific trial to check a main prevention technique to cut back the elevated danger of heart problems amongst individuals dwelling with HIV. It discovered that individuals who took pitavastatin calcium (a day by day statin capsule that lowers ldl cholesterol) lowered their danger of MACE by 36 p.c in contrast with these receiving a placebo over a median length of 5 years of observe up.
“This evaluation from REPRIEVE supplies an in-depth analysis of the metabolic results of switching to an integrase inhibitor,” stated ACTG Chair Joseph J. Eron, M.D., College of North Carolina. “Whereas quite a lot of prior research have reported disproportionate weight achieve amongst individuals dwelling with HIV who initiated remedy with an integrase inhibitor, this is among the few that has evaluated individuals who have been taking different HIV remedies and adopted them for greater than two years after switching to an integrase inhibitor.”
At the moment’s presentation estimated the impact of switching to an integrase inhibitor-based routine on weight problems, diabetes, hypertension, metabolic syndrome, and MACE amongst individuals in REPRIEVE. This evaluation included 2,708 examine individuals who switched to an integrase inhibitor-containing routine, 82 p.c of which included dolutegravir.
High Tales
Article content material
Commercial 3
Article content material
Amongst individuals who switched to an integrase inhibitor-based routine in comparison with those that didn’t, researchers estimated an elevated danger of creating weight problems [hazard ratio (HR): 1.32, 95% confidence interval (CI): 1.07-1.47], diabetes (HR: 1.38, 95% CI: 1.10-1.69), hypertension (HR: 1.38, 95% CI: 1.13, 1.61), and metabolic syndrome (HR: 1.15, 95% CI: 1.00-1.31). They didn’t discover an elevated danger of MACE (HR: 1.03, 95% CI: 0.63, 1.52). Researchers famous that it is going to be vital for future research to find out whether or not taking integrase inhibitors results in heart problems (together with coronary heart assaults and strokes) over the long-term, and to research potential cardiometabolic mechanisms.
“The danger of cardiometabolic issues related to integrase inhibitors was small on this examine,” stated Senior Creator and Examine Chair Steven Grinspoon, M.D., Harvard Medical Faculty. “Nonetheless, on condition that charges of weight problems, diabetes, hypertension, and metabolic syndrome elevated following a change to an integrase inhibitor-based routine, and that these are all vital contributors to heart problems danger, people on integrase inhibitor-containing regimens ought to be intently monitored for cardiometabolic issues over the long run.”
Commercial 4
Article content material
REPRIEVE started in 2015 as cooperative agreements (HL12339, HL123336, HL164284, and HL164285) and was a collaborative effort between the Nationwide Institutes of Well being’s (NIH) Nationwide Coronary heart, Lung, and Blood Institute (NHLBI) and the Nationwide Institute of Allergy and Infectious Ailments (NIAID), two of the most important NIH institutes, and ACTG (AI068636). It acquired extra funding from the NIH Workplace of AIDS Analysis, Kowa Prescription drugs America, Inc. (suppliers of pitavastatin calcium and placebo), Gilead Sciences, Inc., and ViiV HealthCare.
The examine is led by Dr. Grinspoon and Pamela S. Douglas, M.D., Duke College Faculty of Drugs (Co-chair), who led the Scientific Coordinating Heart and Heather Ribaudo, Ph.D., Harvard Faculty of Public Well being (Lead Statistician) and Michael Lu, M.D., M.P.H., Harvard Medical Faculty and Massachusetts Common Hospital (Protocol Chair, Mechanistic Substudy of REPRIEVE), who led the Knowledge Coordinating Heart. ACTG is led by Dr. Eron and Rajesh T. Gandhi, M.D., Massachusetts Common Hospital and Harvard Medical Faculty (ACTG Vice-Chair).
Commercial 5
Article content material
To be taught extra, please go to www.reprievetrial.org.
About ACTG
ACTG is the world’s largest and longest working scientific trials community centered on HIV and different infectious ailments and the individuals dwelling with them. It’s funded by NIAID and collaborating NIH Institutes. Based in 1987, ACTG conducts analysis to enhance the administration of HIV and its comorbidities; develop a remedy for HIV; and innovate remedies for tuberculosis, hepatitis B, and rising infectious ailments. It contains 1000’s of devoted researchers, employees, and group members who’re pursuing analysis into novel remedies and cures for infectious ailments at 65 places throughout 4 continents, with the final word purpose of advancing science that meaningfully impacts the lives of the individuals we serve.
Disclaimer: This content material is solely the accountability of ACTG and doesn’t essentially symbolize the official views of the NIH.
Media Contact:
Rachel Reiss, ACTG
RLReiss@mednet.ucla.edu
Article content material
